Distinguished in Leukoplakia

Dr. Ann M. Gillenwater

Otolaryngology
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Distinguished in Leukoplakia
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ann Gillenwater is an Otolaryngologist in Houston, Texas. Dr. Gillenwater is rated as a Distinguished provider by MediFind in the treatment of Leukoplakia. Her top areas of expertise are Leukoplakia, Tongue Cancer, Oral Squamous Cell Carcinoma, Gastrostomy, and Tissue Biopsy.

Her clinical research consists of co-authoring 55 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Leukoplakia.

Specialties
Otolaryngology
Licenses
Otolaryngology in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders
Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug, Procedure
Study Phase: Early Phase 1
Fluorescence & Reflectance Imaging to Detect Oral Neoplasia
Fluorescence & Reflectance Imaging to Detect Oral Neoplasia
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Enrollment Status: Suspended
Publish Date: September 08, 2025
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 2/Phase 3
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 19, 2025
Intervention Type: Combination product, Biological
Study Drugs: Pembrolizumab, Cemiplimab
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug, Combination product
Study Drugs: ASP-1929, Docetaxel, Cetuximab, Methotrexate, Paclitaxel
Study Phase: Phase 3
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Withdrawn
Publish Date: April 19, 2023
Intervention Type: Combination product, Biological
Study Drugs: RM-1995, Pembrolizumab
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Combination product
Study Phase: Phase 1/Phase 2
Fluorescence and Reflectance Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions
Fluorescence and Reflectance Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions
Enrollment Status: Completed
Publish Date: January 19, 2018
Intervention Type: Procedure
Study Phase: Not Applicable
View 8 Less Clinical Trials

56 Total Publications

Development and Evaluation of an Automated Multimodal Mobile Detection of Oral Cancer Imaging System to Aid in Risk-Based Management of Oral Mucosal Lesions.
Development and Evaluation of an Automated Multimodal Mobile Detection of Oral Cancer Imaging System to Aid in Risk-Based Management of Oral Mucosal Lesions.
Journal: Cancer prevention research (Philadelphia, Pa.)
Published: June 14, 2024
Similar Doctors
Moran Amit
Distinguished in Leukoplakia
Dr. Moran Amit
Otolaryngology
Distinguished in Leukoplakia
Dr. Moran Amit
Otolaryngology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (0.6 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances

Moran Amit is an Otolaryngologist in Houston, Texas. Dr. Amit is rated as a Distinguished provider by MediFind in the treatment of Leukoplakia. His top areas of expertise are Adenoid Cystic Carcinoma, Sinus Cancer, Leukoplakia, Thyroidectomy, and Endoscopy.

Advanced in Leukoplakia
Dr. Kristen B. Pytynia
Otolaryngology
Advanced in Leukoplakia
Dr. Kristen B. Pytynia
Otolaryngology

MD Anderson

13900 Katy Fwy, 
Houston, TX 
 (14.4 miles away)
713-563-9600
Languages Spoken:
English
See accepted insurances

Kristen Pytynia is an Otolaryngologist in Houston, Texas. Dr. Pytynia is rated as a Distinguished provider by MediFind in the treatment of Leukoplakia. Her top areas of expertise are Laryngeal Cancer, Throat Cancer, Thyroid Cancer, Gastrostomy, and Thyroidectomy.

Advanced in Leukoplakia
Dr. Eduardo M. Diaz
Otolaryngology
Advanced in Leukoplakia
Dr. Eduardo M. Diaz
Otolaryngology

MD Anderson

1327 Lake Pointe Pkwy, 
Sugar Land, TX 
 (14.6 miles away)
281-566-1800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eduardo Diaz is an Otolaryngologist in Sugar Land, Texas. Dr. Diaz is rated as a Distinguished provider by MediFind in the treatment of Leukoplakia. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngectomy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gillenwater's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile